Diet & Weight Loss
The GLP-1 group of peptides Semaglutide, Tirzepatide & Retatrutide were all developed to treat type 2 diabetes, used to reduce obesity and each being a more advanced version than the last. Semaglutide, Dulalutide and Liraglutide were the original GLP-1 receptor agonist peptides created, all very similar and sold under more common brand names. Tirzepatide was then released as a dual GLP-1 and GIP receptor agonist and finally Retatrutide was developed as a triple receptor agonist targeting GLP-1, GIP and Glucagon receptors. Other weight loss peptides like AOD-9604 burn fat via a different mechanism.
Semaglutide/Tirzepatide
Semaglutide (Wegovy, Ozempic & Rybelsus) was developed for type 2 Diabetes, it is a GLP-1 agonist. The once weekly injection helps to control blood sugar levels by increasing insulin secretion and reducing glucose production in the liver. Basically the 2 things this does is tell your brain that your full and tell your pancreas to make insulin. Tirzepatide (Mounjaro & Zepbound) is the next 'upgraded dual GLP-1 & GIP agonist' version that was produced, does the same thing but slightly better as includes the prolonged feeling of being full. As a by-product of this users saw a decrease in body weight and positive impacts of weight related issues. Whilst appetite suppression does reduce weight it was found that 70% of that was muscle and connective tissue loss. Once these peptides are stopped if eating habits have not changed weight would likely return.
Retatrutide
Retatrutide is the next in the development following Tirzepitide, this wonder drug is a triple agonist combining the GLP-1, GIP & Glucagon. The multi-receptor approach distinguishes it from other weight loss medications to suppress appetite, slow digestion, and boost fat burning, leading to dramatic weight loss. Aside from fat loss in trials Retatrutide improved blood sugar/lipids, reduced liver fat, and better heart health markers including blood pressure and cholesterol. Other potential benefits where this is showing promise are PCOS, sleep apnoea & knee osteoarthritis. Without going too science geek on you, its our opinion this peptide is going to change the extent of obesity and actually assist/correct other issues if used correctly.
This is one peptide that actually needs carbohydrates to function optimally (not 4 cheeseburgers and a cooked breakfast swimming in butter) but going keto on this peptide in our opinion will limit your results.
AOD-9604
AOD-9604, also known as the Advanced Obesity Drug, is a modified fragment of human growth hormone (amino acids 176–191) developed to isolate the fat-burning properties of HGH while avoiding its anabolic effects and IGF-1 stimulation. It activates beta-3 adrenergic receptors in adipose tissue, promoting the breakdown of stored fat into glycerol and fatty acids for energy use, while simultaneously preventing new fat formation. This mechanism allows for targeted fat loss, particularly in abdominal regions, without triggering the broader hormonal effects associated with HGH. Additionally, AOD-9604 has been shown to support cartilage and bone repair, especially when combined with peptides like BPC-157, and may aid in osteoarthritis treatment. Clinical studies and preclinical trials indicate minimal side effects, with no significant impact on insulin sensitivity or IGF-1 levels.